We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.55% | 9.15 | 8.80 | 9.50 | 9.15 | 8.86 | 9.10 | 1,054,095 | 12:15:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.09 | 84.9M |
TIDMSCLP
RNS Number : 0317B
Scancell Holdings Plc
18 September 2018
18 September 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Notice of Final Results
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, will announce its financial results for the year ended 30 April 2018 on Tuesday, 25 September 2018.
For Further Information:
Scancell Holdings Plc Dr John Chiplin, Chairman +44 (0) 20 3727 1000 Dr Cliff Holloway, CEO Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker) Freddy Crossley/Emma Earl +44 (0) 20 7886 2500 FTI Consulting Mo Noonan/Simon Conway +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
-- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.
Moditope(R) represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours. allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope(R) alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website: www.scancell.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORBLGDCXXBBGIR
(END) Dow Jones Newswires
September 18, 2018 02:02 ET (06:02 GMT)
1 Year Scancell Chart |
1 Month Scancell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions